Consultant Haematologist (Myeloid Disorders & Stem Cell) | The Christie NHS Foundation Trust
| Dyddiad hysbysebu: | 20 May 2024 |
|---|---|
| Cyflog: | Heb ei nodi |
| Gwybodaeth ychwanegol am y cyflog: | £99,532 - £131,964 per annum |
| Oriau: | Full time |
| Dyddiad cau: | 19 June 2024 |
| Lleoliad: | Manchester, M20 4BX |
| Cwmni: | The Christie NHS Foundation Trust |
| Math o swydd: | Permanent |
| Cyfeirnod swydd: | 6325625/413-MD-C2024-23726 |
Crynodeb
The Christie Haematology Team are looking for an experienced Consultant with subspecialty training in myeloid disorders to join an established team who is enthusiastic about providing a high-quality service to our patients. This job role is for 10 PAs per week to support the development of the myeloid and stem cell transplant services, with on call responsibilities attached. The post holder will be based at our Withington site and will be willing to travel and work at our satellite centres.
Flexibility may be considered for those who are unable to work full-time due to personal reasons.
The successful post holder will undertake three clinics per week, providing continued care for patients in their charge. It is expected that the post holder will have an interest and active role in teaching, supporting junior clinical students with their development.
The post holder will be responsible for providing consultant level support to the development of the myeloid service and to implement best practice in Haematology. They will be a core member of the GMCCN Southern Sector MDT and will act as a leader for transplantation in myeloid disorders.
A full and extensive overview of the responsibilities are detailed in the job description attached.
The Christie is one of Europe’s leading cancer centres, treating over 60,000 patients a year. We are based in Manchester and serve a population of 3.2 million across Greater Manchester & Cheshire, but as a national specialist around 15% patients are referred to us from other parts of the country.
We provide radiotherapy through one of the largest radiotherapy departments in the world; chemotherapy on site and through 14 other hospitals; highly specialist surgery for complex and rare cancer; and a wide range of support and diagnostic services. We are also an international leader in research, with world first breakthroughs for over 100 years.
We run one of the largest early clinical trial units in Europe with over 300 trials every year. Cancer research in Manchester, most of which is undertaken on the Christie site, has been officially ranked the best in the UK.
The Christie acts as a tertiary referral centre for management of patients with haematological malignancies and bone marrow failure. The Trust does not currently accept direct GP referrals. The Haematology department currently sees around 1000 new patients, 15000 follow up patients and admits 2000 patients per year.
Myeloid disorders - Clinical Service
The myeloid disorders service treats the full spectrum of myeloid blood cancers and bone marrow failure syndromes. A high proportion of the patients cared for have complicated disease requiring tertiary referral centre input and management over and above that which can routinely be delivered within a district general hospital setting. Due to the reputation and quality of the service provided, referrals are received from across the North-West and North Wales, with the service additionally providing support and input to consultant colleagues in local hospitals. The service is strongly research active, both scientifically and from a clinical trials viewpoint. A real strength of the service is the range of clinical trial options available to patients both within the myeloid clinic itself, but also supported and added to by consultant colleagues in the early phase trials service.
Myeloid disorders - Stem Cell Transplantation
Myeloid disorders constitute the major indications for allogeneic stem cell transplantation which is the only potentially curative therapy for patients with life threatening disease. Data from the European Society for Blood and Marrow Transplantation 2021 activity survey shows that more than 50% of allogeneic transplants are undertaken for myeloid disease, with increasing numbers of transplants performed over the last 30 years. A similar trend has been observed in patients treated for AML and MDS (the most common indications for transplant) at The Christie over a similar time period. With the advent of less toxic transplant conditioning protocols, transplants are now increasingly being performed in older patients which represent the majority of cases and will further drive increased transplant activity. This post will support anticipated growth in transplant activity offering this life-saving therapy to more patients.
This advert closes on Monday 10 Jun 2024
Aelod balch o'r cynllun cyflogwyr Hyderus o ran Anabledd
Hyderus o ran Anabledd
Gwybodaeth am Hyderus o ran Anabledd
Yn gyffredinol, bydd cyflogwr Hyderus o ran Anabledd yn cynnig cyfweliad i unrhyw ymgeisydd sy'n datgan eu bod yn anabl ac yn bodloni'r meini prawf lleiaf ar gyfer y swydd fel y diffinnir gan y cyflogwr. Mae'n bwysig nodi, mewn rhai sefyllfaoedd recriwtio fel nifer fawr o ymgeiswyr, cyfnod tymhorol ac amseroedd prysur iawn, efallai y bydd y cyflogwr am gyfyngu ar y niferoedd cyffredinol o gyfweliadau a gynigir i bobl anabl a phobl nad ydynt yn anabl. Am fwy o fanylion ewch i Hyderus o ran Anabledd.